Biotech China 2014

View Profile


Peer Reviewed Papers, Books, Chapters

Year Title Citation Authors
1. 2009 Activation of mTORC1 signaling pathway in AIDS-related lymphomas (ARL). Am. J. Pathol., in press.
2. 2008 Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-LI, B7-H1). Proc. Natl. Acad. Sci. USA, 105: 20852-20857
3. 2008 Malignant Tregs express low molecular splice forms of FOXP3 in Sézary syndrome Leukemia, 22: 2230-2239
4. 2008 gc-signaling cytokines induce a regulatory T cell (Treg) phenotype in malignant CD4+ T lymphocytes. J Immunol, 181: 2506-2512
5. 2008 Differential effects of interleukin(IL)-2 and IL-15 versus IL-21 on CD4+ cutaneous T-cell lymphoma cells. Cancer Res., 68:1083-1091
6. 2008 IL-2- and IL-15-induced activation of the rapamycin-sensitive mTORC1 pathway in malignant CD4+ T lymphocytes. Blood, 111: 2181-2189
7. 2008 AH Rook. IL-21 enhances antitumor responses without stimulating proliferation of malignant T-cells of patients with cutaneous T-cell Lymphoma. J Invest Derm, 128: 473-480
8. 2007 Stat5a is epigenetically silenced in the NPM/ALK-transformed T lymphocytes and acts in such cells as tumor suppressor by inhibiting expression of the NPM/ALK oncogene. Nature Med. Nature Med., 13:1341-1348
9. 2007 Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway Oncogene, 26:5606-5614
10. 2007 Non-malignant T cells stimulate growth of T-cell lymphoma cells in the presence of bacterial toxins. Blood, 109:3325-3332
11. 2007 Constitutive activation of mTOR signaling pathway in post-transplant lymphoproliferative disorders (PTLDs). Lab Invest, 87:29-39
12. 2007 PU.1 regulates transcription of SHP-1 in hematopoietic cells J Biol Chem, 282:6316-6323
13. 2007 Loss of SHP-1 tyrosine phosphatase expression correlates with the advanced stages of cutaneous T-cell lymphoma (CTCL). Human Path, 38:462-467
14. 2007 Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf. Oncogene 26:813-21
15. 2006 PPARg promotes lymphocyte survival through its actions on cellular metabolic activities J. Immunol., 177: 3737-3745
16. 2006 Mantle cell lymphoma cells express predominantly Cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity. Blood, 108: 1744-1750,
17. 2006 NPM/ALK oncoprotein induces T regulatory cell phenotype by activating STAT3. Proc. Natl. Acad. Sci. USA, 103: 9964-9969
18. 2006 STAT3 induces transcription of the DNA methyltransferase 1 (DNMT1) gene in malignant T-lymphocytes Blood, 108: 1058-1064
19. 2006 Expression and oncogenic role of Brk (PTK6/Sik) protein tyrosine kinase in lymphocytes Am. J. Pathol., 168: 1631-1641
20. 2006 STAT5-induced Id1 transcription inhibitor/MMP9 metalloprotease axis enhances invasiveness of the BCR/ABL-transformed leukemic cells. Cancer Res., 66: 4108-4116
21. 2006 Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma. Oncogene, 25: 998-1007
22. 2006 Multi-gene epigenetic silencing of tumor suppressor genes in T-cell lymphoma cells; delayed expression of the p16 protein upon reversal of the silencing Leuk. Res., 30: 303-312
23. 2005 Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3 Lab. Invest., 85: 1544-1554
24. 2005 Activation of mTOR in transformed B lymphocytes is nutrient-dependent but independent of Akt, MEK, IGF-I, and serum Cancer Res., 65: 7800-7808
25. 2005 Constitutive SOCS-3 expression protects T-cell lymphoma against growth inhibition by IFNa Leukemia, 19: 209-213
26. 2005 Treatment of primary Epstein-Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell directed therapy. Blood, 105:994-996
27. 2003 Detection of protein tyrosine-kinase (PTK) gene expression pattern in normal and malignant T lymphocytes by combined PTK-specific PCR and parallel denaturing gradient gel electrophoresis (DGGE). J. Mol. Diagn., 5: 113-120
28. 2003 Immunosuppressive signal transduction inhibitor RAD suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft protecting doses. Transplantation, 75: 1710-1717
29. 2002 SHP2 regulates IL-2 induced MAPK activation, but not Stat3 or Stat5 tyrosine phosphorylation, in cutaneous T cell lymphoma cells Cytokine, 20:141-147
30. 2002 Diminished expression of the type II receptor for TGFß in T cells from patients with Sezary Syndrome is not due to mutations in the receptor’s poly-A tract: limitations of RT-PCR in cDNA sequence analysis of homopolymeric base stretches Arch. Immunol. Ther. Exp., 50: 421- 429
31. 2002 Expression of SHP-1 phosphatase indicates post-germinal center cell derivation of the B-cell post-transplant lymphoproliferative disorders (PTLDs). Lab. Invest., 82: 1599-1606
32. 2002 Complementary functions of the anti-apoptotic protein A1 and serine/threonine kinase pim-1 in the BCR/ABL-mediated leukemogenesis Blood, 99: 4531-4539
33. 2002 Multilevel dysregulation of STAT3 activation in ALK+ T/null-cell lymphoma J. Immunol, 168: 466-474
34. 2001 Role of signal transducer and activator of transcription 5 in nucleophosmin/ anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells Cancer Res 61: 6517-6523
35. 2001 Constitutive STAT3-activation in Sezary Syndrome (SS): tyrphostin AG490 inhibits STAT3- activation, interleukin-2 receptor expression and growth of leukemic Sezary cells Leukemia, 15: 787-793
36. 2001 Comparative genome-scale analysis of gene expression in T-cell lymphoma during malignant progression using a complementary DNA microarray. Am. J. Path., 158: 1231-1237
37. 2001 Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis Cancer Res., 61: 2194-2199
38. 2001 STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma Blood, 97: 1056-1061
39. 2000 Bcl 2 expression restores the leukemogenic potential of a BCR/ABL mutant defective in transformation Blood, 96: 3915-3921
40. 2000 Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter. Am. J. Path., 157: 1137-1146
41. 2000 Immunosuppressive macrolide SDZ RAD inhibits growth of human EBV-transformed B lymphocytes in vitro and in vivo; a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders (PTLDs). Proc. Natl. Acad. Sci. USA, 97: 4285-4290
42. 1999 Signal transducer and Activator of Transcription (STAT)5 activation by BCR/ABL is dependent on intact src homology (SH3) and SH2 domains of BCR/ABL and is required for leukemogenesis. J. Exp. Med., 189; 1229-1242
43. 1998 BCR/ABL SH3-mediated leukemogenesis requires activity of the small GTP-binding protein Rac. Proc. Natl. Acad. Sci. USA, 95: 11858-11862
44. 1998 Use of serum soluble interleukin-2 receptor levels to monitor patients with cutaneous T cell lymphoma treated with extracorporeal photophoresis J. Am. Acad. Dermatol., 38: 207-220
45. 1996 Blastic transformation of p53-deficient bone marrow cells by p210BCR/ABL tyrosine kinase. Proc. Natl. Acad. Sci. USA, 93: 13137-13142
46. 1996 Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. Proc. Natl. Acad. Sci. USA, 93: 9148-9153


4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.